on GENSIGHT BIOLOGICS S.A. (EPA:SIGHT)
GenSight Biologics Secures €1.7 Million in Fresh Fundraising
GenSight Biologics announced a successful fundraising of approximately €1.7 million, involving key shareholders Heights Capital, Invus, and UPMC Enterprises. This comes on the heels of several fundraisings in 2025, including a €4.5 million private placement and multiple smaller fundraisings. The recent investment employs a mixture of shares and warrants.
The funding helps to extend GenSight's cash reserves and supports the progression to the RECOVER Phase III trial. GenSight plans to leverage these resources to initiate treatments in France, Israel, and the United States, as part of their clinical expansion.
The fundraising activities are part of GenSight's broader strategy to ensure financial stability and operational continuity through 2026, despite unpredictable payment timings from the French hospital system. The shares and warrants issued are aligned with regulatory stipulations to facilitate their addition to Euronext Paris trading.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENSIGHT BIOLOGICS S.A. news